Cargando…

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma

The measurement of serum-free light chains (FLC) is standard of care in the diagnosis and management of multiple myeloma (MM). The revised international myeloma working group (IMWG) implemented the involved FLC/noninvolved FLC (iFLC/niFLC) ratio as a biomarker for MM requiring treatment. Recently, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schieferdecker, Aneta, Hörber, Sebastian, Ums, Monika, Besemer, Britta, Bokemeyer, Carsten, Peter, Andreas, Weisel, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949235/ https://www.ncbi.nlm.nih.gov/pubmed/31915365 http://dx.doi.org/10.1038/s41408-019-0267-8

Ejemplares similares

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022)

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
por: Leypoldt, Lisa B., et al.
Publicado: (2023)

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response
por: Shimizu, Kazuyuki, et al.
Publicado: (2017)

Light chain myeloma and detection of free light chains in serum and urine of dogs and cats
por: Harris, Robert Adam, et al.
Publicado: (2021)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients
por: Zamani, Fatemeh, et al.
Publicado: (2021)

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies
por: Tietsche de Moraes Hungria, Vania, et al.
Publicado: (2016)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

Serum Free Light Chain Only Myeloma with Cytoplasmic IgM
por: Ebana, Hideaki, et al.
Publicado: (2014)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
por: Wilhite, Dorian, et al.
Publicado: (2021)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients
por: García de Veas Silva, José Luis, et al.
Publicado: (2016)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients
por: Sprangers, Ben, et al.
Publicado: (2020)

Analytical and clinical concordance of free light chain assay
por: Smith, Andrew, et al.
Publicado: (2018)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study
por: Yadav, Punit, et al.
Publicado: (2020)

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
por: Leypoldt, Lisa B., et al.
Publicado: (2021)

CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021)

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
por: Michallet, M, et al.
Publicado: (2018)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
por: De Santis, Elena, et al.
Publicado: (2016)

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial
por: Hutchison, Colin A, et al.
Publicado: (2008)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL
por: Leypoldt, L., et al.
Publicado: (2022)

Silver Nanoparticle-Based Assay for the Detection of Immunoglobulin Free Light Chains
por: Lizoń, Anna, et al.
Publicado: (2019)

Verification study of free light chains assays on reagent-optimized analysers
por: Šegulja, Dragana, et al.
Publicado: (2019)

Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results
por: Singh, Gurmukh
Publicado: (2017)

Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma
por: Benson, Rony, et al.
Publicado: (2020)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
por: Braig, Friederike, et al.
Publicado: (2016)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
por: Bilich, Tatjana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bl3uqell1v6sqr4qhm0u181mhu